Details for Patent: 6,037,157
✉ Email this page to a colleague
Title: | Method for improving pharmacokinetics |
Abstract: | A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase. |
Inventor(s): | Norbeck; Daniel W. (Crystal Lake, IL), Kempf; Dale J. (Libertyville, IL), Leonard; John M. (Lake Bluff, IL), Bertz; Richard J. (Kenosha, WI) |
Assignee: | Abbott Laboratories (Abbott Park, IL) |
Filing Date: | Jun 26, 1996 |
Application Number: | 08/687,774 |
Claims: | 1. A method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase comprising administering to a human in need of such treatment a therapeutically effective amount of a combination of said drug or a pharmaceutically acceptable salt thereof and ritonavir or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of cyclosporine, FK-506, rapamycin, taxol , taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017. 3. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017. 4. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343. 5. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is saquinavir. 6. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is VX-478. 7. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is MK-639. 8. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is AG1343. 9. A method for increasing human blood levels of a drug which is metabolized by cytochrome P450 monooxygenase comprising administering to a human in need of such treatment a therapeutically effective amount of a combination of said drug or a pharmaceutically acceptable salt thereof and ritonavir or a pharmaceutically acceptable salt thereof. 10. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of cyclosporine, FK-506, rapamycin, taxol , taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017. 11. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017. 12. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343. 13. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is saquinavir. 14. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is VX-478. 15. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is MK-639. 16. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is AG1343. 17. A method for inhibiting cytochrome P450 monooxygenase comprising administering to a human in need thereof an amount of ritonavir or a pharmaceutically acceptable salt thereof effective to inhibit cytochrome P450 monooxygenase. 18. A method for inhibiting cytochrome P450 monooxygenase comprising contacting the cytochrome P450 monooxygenase with an amount of ritonavir or a pharmaceutically acceptable salt thereof effective to inhibit cytochrome P450 monooxygenase. |